Study Demonstrates Symptom Improvement in Adult Women with IBS-C

New Phase III study results indicate that treatment with Amitiza 8 micrograms led to significant relief of overall symptoms of irritable bowel syndrome with constipation (IBS-C) in adult women.

The drug was developed by Sucampo Pharmaceuticals and is co-marketed in the U.S. by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.

Amitiza (lubiprostone) 8 micrograms was approved by the FDA last month for the treatment of IBS-C in women age 18 years and older. It has been approved since 2006 at a 24-microgram dose for the treatment of chronic idiopathic constipation in adults, according to Sucampo.